Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant meningococcal group b vaccine (Zhifei Lvzhu)
- Development stage
- Phase 1
- Lead developer
- Zhifei Biological
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant meningococcal group B vaccine is a protein-based vaccine candidate developed by Beijing Zhifei Lvzhu Biopharmaceutical for the prevention of invasive disease caused by *Neisseria meningitidis* serogroup B. Unlike serogroups A, C, W, and Y, which are targeted by polysaccharide conjugate vaccines, serogroup B's capsular polysaccharide is poorly immunogenic due to its structural similarity to human glycoproteins. This vaccine employs recombinant proteins expressed in *E. coli* to bypass this limitation and elicit a protective immune response. It is currently being evaluated in Phase I clinical trials (e.g., CTR20231293) to assess safety, tolerability, and immunogenicity across a broad age range from 3 months to 50 years.
- Other names
- Recombinant Meningococcal Group B Vaccine (E.coli)
02
Targets
fHbp (Factor H-binding protein)PorANHBA (Neisserial heparin-binding antigen)
Beyond the preview
Go deeper on recombinant meningococcal group b vaccine (Zhifei Lvzhu).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant meningococcal group b vaccine (Zhifei Lvzhu).